Skip to content

#ADC/偶联药物

Today 0 items
Sep 9Wed
  1. biocentury.com60

    GSK takes rights to Hutchmed’s KRAS-antibody conjugate: Deals Report

    GSK plc is paying $110 million up front for most global rights to HMPL-A830, a dual-targeted oncology therapy from Hutchmed China that links a KRAS inhibitor payload to an anti-EGFR antibody. HMPL-A830 is the first deal from Hutchmed's Antibody-Targeted Therapy Conjugate (ATTC) platform, which has also produced two PI3K-payload programs now in Phase I testing. The same report also covers Alteogen's delivery-tech deal with Novartis and Menarini's local in-licensing of Gan & Lee's obesity program.

    Why it matters: First licensing deal from Hutchmed's ATTC platform gives GSK most global rights to a KRAS-antibody conjugate.

Sep 3Thu
  1. fiercebiotech.com64

    GSK pens $1.3B Hutchmed deal for early-stage KRAS-EGFR cancer asset

    GSK has licensed Hutchmed's preclinical KRAS-EGFR antibody conjugate HMPL-A830, paying $110 million upfront in a deal worth up to $1.295 billion, excluding Mainland China, Hong Kong, Macau and Taiwan. The candidate delivers a KRAS inhibitor to EGFR-expressing tumors and is slated to enter trials later this year, initially in colorectal, pancreatic and lung cancer. Hutchmed will run Phase 1 trials, after which GSK takes over R&D and commercialization outside select Asian territories.

    Why it matters: GSK is paying up to $1.295 billion for a preclinical first-in-class KRAS-EGFR candidate, a notable early-stage oncology licensing deal.

Aug 28Fri
  1. fiercebiotech.com57

    Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact

    Roche's Genentech is paying DualityBio $45 million upfront for rights to antibody-drug conjugates built on the Chinese biotech's Dupac platform, with the deal worth more than $1 billion in potential milestones. DualityBio will generate and develop ADCs that deliver Dupac payloads, designed to retain efficacy in tumors that progress on topoisomerase-based ADCs such as Enhertu and Trodelvy, to Genentech-picked targets, with Genentech taking sole responsibility for development after phase 1a. BioNTech, GSK and BeiGene struck earlier deals for DualityBio ADCs in 2023 and 2024.

    Why it matters: A $1 billion licensing deal targeting patients who progress on approved ADCs addresses a growing unmet clinical need.

Aug 24Mon
  1. fiercepharma.com47

    Daiichi Sankyo promotes Ken Keller to lead new commercialization unit

    Daiichi Sankyo has promoted Ken Keller, who has led its global oncology business for five years, to chief commercialization officer of a new globally integrated commercialization unit starting April 1. The restructured organization covers five regions, with internal appointments including Yuichi Yomasu in China, Markus Kosch in Europe, Marcelo Goncalves in Latin America, Kenji Shigeta in North America and Nobuo Murakami in Japan, Asia and the Pacific. The unit supports Daiichi Sankyo's plan to become a top-five oncology company by 2035 and to make five drugs available in 20 new indications by 2030.

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org